ABSTRACT
Objective To analyse clinical efficacy of Fangfengtongsheng powder combined with Flupentixol and Melitracen tablets in treatment of anorectal neurosis.Methods92 patients with anorectal neurosis from April 2014 to June 2016 were grouped two groups randomly, each with 46 cases.Two groups were treated with Flupentixol and Melitracen tablets and observation group was treated another with Fangfengtongsheng powder.Clinical efficacy of two groups were compared.Results①Total effective rate of observation group was 95.65%,higher than that of control group 78.26% (P<0.05).②After treatment,SAS and SDS score of observation group were lower than that of control group(P<0.05).③After treatment, anal bulge, anal pain, frequent defecation, anal foreign body sensation score and 8 dimensions of SF-36 scale score of observation group were better than that of control group(P<0.05).④The control group had 8.70% adverse reactions, compared with observation group 4.35%, the difference was not statistically significant.ConclusionFangfengtongsheng powder can improve the therapeutic effect of anorectal neurosis on the basis of Flupentixol and Melitracen tablets, relieve the anxiety level and improve the living standard of patients.
ABSTRACT
Objective To observe the efficacy of advanced non-small cell lung cancer patients treated with CIK cell combined with chemotherapy.Methods65 cases of advanced lung cancer patients admitted in our hospital from February 2013 to January 2015 were retrospectively analyzed.The patients were randomly divided into observation group (34 cases) and control group (n=31).The levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9) and carcinoembryonic antigen (CEA) in the two groups were observed before and after treatment.The patients in the control group were treated with chemotherapy on the basis of chemotherapy.Cytokeratin 19 (CYFRA21-1) levels, and clinical efficacy.Results①The patients with VEGF and MMP-9 values after treatment (298.67±36.49)ng/L, (1102.31±86.48)ng/mL, than the control group (459.19±45.28)ng/L, (1394.83±121.06)ng/mL, and the difference was significant (P<0.05).②CEA and CYFR21-1 value patients in the observation group were (14.16±1.08) ng/mL, (4.45±0.45) ng/mL, than the control group (17.86±1.84) ng/mL, (5.76±0.64) ng/mL, and the difference was significant (P<0.05).③The total observation group was significantly higher than patients 94.18% 74.19% efficiency, and the difference was statistically significant (P<0.05).ConclusionCIK cell biological therapy combined with chemotherapy for advanced lung cancer patients with a certain improvement is worthy of further research and application.